Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-25 4:26 pm Purchase |
2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX |
Novo Holdings A/S | 6,344,430 7.400% |
272,727 (+4.49%) |
Filing History |
| 2024-01-25 4:25 pm Purchase |
2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,756,096 17.300% |
454,545 (+3.18%) |
Filing History |
| 2023-06-28 4:17 pm Unchanged |
2023-06-19 | 13D | Edgewise Therapeutics, Inc. EWTX |
Novo Holdings A/S | 6,071,703 9.600% |
0 (Unchanged) |
Filing History |
| 2023-02-14 3:06 pm Sale |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
Cormorant Global Healthcare Master Fund LP | 2,946,887 4.660% |
-619,014 (-17.36%) |
Filing History |
| 2023-02-14 1:17 pm Purchase |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 4,409,146 7.000% |
1,681,897 (+61.67%) |
Filing History |
| 2023-02-14 08:14 am Purchase |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
Citadel Advisors LLC | 2,849,354 4.500% |
360,070 (+14.46%) |
Filing History |
| 2023-02-10 10:01 am Unchanged |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
Flynn James E | 3,933,137 6.220% |
0 (Unchanged) |
Filing History |
| 2023-02-09 10:59 am Purchase |
2023-02-09 | 13G | Edgewise Therapeutics, Inc. EWTX |
FMR CORP | 8,589,229 13.587% |
612,416 (+7.68%) |
Filing History |
| 2023-02-01 1:38 pm Sale |
2022-02-25 | 13D | Edgewise Therapeutics, Inc. EWTX |
U.S. Venture Partners XI L.P. | 15,625 0.000% |
-3,473,543 (-99.55%) |
Filing History |
| 2022-10-11 09:03 am Purchase |
2022-10-07 | 13G | Edgewise Therapeutics, Inc. EWTX |
FMR CORP | 7,976,813 12.631% |
5,476,714 (+219.06%) |
Filing History |
| 2022-09-30 4:47 pm Unchanged |
2022-09-27 | 13D | Edgewise Therapeutics, Inc. EWTX |
Novo Holdings A/S | 6,071,703 9.600% |
0 (Unchanged) |
Filing History |
| 2022-09-26 4:06 pm Purchase |
2022-09-14 | 13G | Edgewise Therapeutics, Inc. EWTX |
EcoR1 Capital LLC | 3,493,194 5.500% |
3,493,194 (New Position) |
Filing History |
| 2022-09-23 4:11 pm Purchase |
2022-09-14 | 13G | Edgewise Therapeutics, Inc. EWTX |
Deep Track Capital, LP | 3,374,394 5.340% |
3,374,394 (New Position) |
Filing History |
| 2022-09-16 4:23 pm Purchase |
2022-09-16 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,301,551 23.300% |
622,496 (+4.55%) |
Filing History |
| 2022-09-16 2:27 pm Purchase |
2022-09-14 | 13D | Edgewise Therapeutics, Inc. EWTX |
Novo Holdings A/S | 6,071,703 9.600% |
484,496 (+8.67%) |
Filing History |
| 2022-08-15 4:59 pm Sale |
2022-08-15 | 13G | Edgewise Therapeutics, Inc. EWTX |
RA Capital Management, L.P. | 0 0.000% |
-2,613,623 (Position Closed) |
Filing History |
| 2022-02-14 5:02 pm Sale |
2021-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 2,727,249 5.500% |
-625,032 (-18.64%) |
Filing History |
| 2022-02-14 4:11 pm Purchase |
2021-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
RA Capital Management, L.P. | 2,613,623 5.300% |
2,613,623 (New Position) |
Filing History |
| 2022-02-14 3:13 pm Purchase |
2021-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
Cormorant Global Healthcare Master Fund LP | 3,565,901 7.230% |
974,987 (+37.63%) |
Filing History |
| 2022-02-09 09:11 am Purchase |
2022-02-08 | 13G | Edgewise Therapeutics, Inc. EWTX |
FMR CORP | 2,500,099 5.071% |
2,500,099 (New Position) |
Filing History |